期刊文献+

Ⅱ类主要组织相容性复合物转录激活子(MHC2TA)-168A→G多态性与冠心病的相关性研究

Study on the correlation between MHC2TA-168A→G polymorphism and coronary heart disease(CHD) in Han Chinese population
下载PDF
导出
摘要 目的研究Ⅱ类主要组织相容性复合物转录激活子(MHC2TA)-168A→G多态性在中国汉族人群中的分布及与冠心病的相关性。方法采用错配聚合酶链反应-限制性片段长度多态性技术(mpPCR-RFLP),对汉族185例冠心病患者及149名正常人群MHC2TA基因-168A→G位点进行研究。结果冠心病组与对照组均检出-168AA、-168AG和-168GG基因型,MHC2TA-168A等位基因频率分别为0.724和0.802,MHC2TA-168G等位基因频率分别为0.276和0.198,冠心病组MHC2TA-168G基因型频率(0.276)明显高于对照组(0.198。OR:1.542,95%CI:1.070~2.221;P<0.05。结论MHC2TA-168A→G多态性与冠心病有关,G等位基因可能是汉族人群冠心病的遗传危险因素。 Objective To investigate the correlation between Major Histocompability Complex Class Ⅱ Transactivator (MHC2TA) - 168A→ G polymorphism and CHD in Han Chinese population. Methods Using the methods of misparing polymerase chain reaction - restriction fragment length polymorphism (mpPCR-RFLP) , followed by DNA sequencing identification, 185 CHD patients and 149 controls were analyzed for the polymorphism , genotype and allele distribution of MHC2TA - 168A→G . Results Genetypes of - 168AA, - 168AG and - 168Gg were found both in patients of CHD and those in normal control . The MHC2TA - 168A allele frequency in CHD patients and normal control was 0.724 and 0. 802 respectively , that in CHD group was much higher than that in control group( OR:1. 542 , 95 % CI: 1. 070 - 2. 221 ; P 〈 0.05 ) . Conclusions MHC2TA - 168A→G polymorphism is associated with CHD risk of Hart Chinese population , the G allele may serve as a genetic risk factor of coronary heart disease.
出处 《浙江临床医学》 2008年第2期147-149,共3页 Zhejiang Clinical Medical Journal
关键词 冠状动脉粥样硬化性心脏病 Ⅱ类主要组织相容性复合物转录激活子 基因多态性 Coronary Heart Disease Major Histocompability Complex Class Ⅱ Transactivator(MnC2TA) Gene Polymorphism
  • 相关文献

参考文献12

  • 1Hansson GK. Inflammation atherosclerosis and coronary artery disease. N Engl J Med , 2005,352:1685 - 1695.
  • 2Swanberg M, Lidman O, Padyukov L, et al. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial inffarction. Nat Genet, 2005, 37: 486- 494.
  • 3Akkad DA, Jaglello P, Szyld P, et al. Promotor polymorphism rs3087456 in the MHC clasps II transactivator gene is not associated with susceptibility for selected autoimmune diseases in German patient groups. International Journal of Immunogenetics, 2006 , 33:59-61.
  • 4Nagarajan UM, Bushey A, Boss JM. Modulation of gene expression by the MHC class Ⅱ transactivator. J Immunol, 2002, 169:5078 - 5088.
  • 5Ting JP, Trowsdale J. Genetic control of MHC class Ⅱ expression. Cell, 2002, 109:21 - 33.
  • 6Boss JM, Jensen PE. Transcriptional regulation of the MHC class Ⅱ antigen presentation pathway. Curt Opin Immunol, 2003, 15: 105 - 111.
  • 7Nozell S, Ma Z, Wilson C, et al. Class Ⅱ Major Histocompatibility Complex Transactivator (CIITA) Inhibits Matrix Metalloproteinase - 9 Gene Expression. The Journal of Biological Chemistry, 2004, 38 : 577 - 589.
  • 8Ting JP, Trowsdale J. Genetic control of MHC class Ⅱ expression. Cell , 2002, 109, 21- 33.
  • 9Lindholm E, Melander O, Ahngren P, et al. Polymorphism in the MHC2TA Gene .Is Associated with Features of the Metabolic Syndrome and Cardiovascular Mortality. PLoS ONE,2006, 1 ( 1 ) : 1-64.
  • 10Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med, 2000, 6:1399 - 1402.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部